About HLA class II histocompatibility antigen, DR beta 5 chain
HLA class II histocompatibility antigen, DR beta 5 chain (HLA-DRB5) is a protein
from Homo sapiens identified by UniProt accession
Q30154, 266 residues long.
MolForge cross-references it against 0 known binders and
238 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DR beta 5 chain |
|---|
| UniProt accession | Q30154 |
|---|
| Gene | HLA-DRB5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 266 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (238)
Diseases linked to this target (Open Targets).
- psoriasis vulgaris · score 0.30
- monocyte percentage of leukocytes · score 0.29
- psoriasis · score 0.28
- leukocyte count · score 0.28
- neutrophil count · score 0.21
- grip strength measurement · score 0.20
- monocyte count · score 0.20
- seasonal allergic rhinitis · score 0.19
- high density lipoprotein cholesterol measurement · score 0.19
- endometrial cancer · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q30154-F1 | alphafold | PREDICTED | 86.76 | — |
Amino-acid sequence (266 residues)
MVCLKLPGGS YMAKLTVTLM VLSSPLALAG DTRPRFLQQD KYECHFFNGT ERVRFLHRDI YNQEEDLRFD SDVGEYRAVT ELGRPDAEYW NSQKDFLEDR RAAVDTYCRH NYGVGESFTV QRRVEPKVTV YPARTQTLQH HNLLVCSVNG FYPGSIEVRW FRNSQEEKAG VVSTGLIQNG DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAQ SESAQSKMLS GVGGFVLGLL FLGAGLFIYF KNQKGHSGLH PTGLVS
Explore HLA class II histocompatibility antigen, DR beta 5 chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets